CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- 4 Open-market sale Chief Scientific Officer sold 5,336 shares at an average $41.27 ($220,201)
- 4 Open-market sale Chief Commercial Officer sold 5,400 shares at an average $41.22 ($222,607)
- 4 Open-market sale Chief Accounting Officer sold 5,370 shares at an average $41.26 ($221,579)
- 5 Insider Annual Insider Trading Report
- 4 Open-market sale Chief Commercial Officer sold 48,910 shares at $41.19 ($2,014,603)
- 4 Open-market sale Chief Medical Officer sold 54,849 shares at $41.19 ($2,259,230)
- 4 Grant or award Chief Executive Officer acquired 147,000 shares (grant or award)
- 4 Grant or award Atillasoy Ercem acquired 28,000 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 43,750 shares (grant or award)
- 4 Grant or award Director acquired 58,800 shares (grant or award)
- 4 Grant or award Chief Accounting Officer acquired 17,500 shares (grant or award)
- 4 Grant or award Chief Scientific Officer acquired 28,000 shares (grant or award)
- 4 Grant or award General Counsel acquired 28,000 shares (grant or award)
- 4 Grant or award Chief Commercial Officer acquired 35,000 shares (grant or award)
- 3/A Insider 3/A
- 4 Conversion Director acquired 2,436,773 shares (conversion)
- 4 Conversion Director acquired 5,532,757 shares (conversion)
- 4 Conversion Director acquired 20,583 shares (conversion)
- 4 Conversion General Counsel acquired 32,759 shares (conversion)
- 4 Conversion Chief Scientific Officer acquired 2,436,773 shares (conversion)
Page 16 of 19 · 363 filings